XELJANZ CAUSING PULMONARY EMBOLISM LAWSUIT ATTORNEY

Personal Injury Law Firm Offices in Longview, TX, Tyler, TX & Shreveport, LA

Pfizer's arthritis drug Xeljanz® increases the risk of death and blood clots in the lungs (pulmonary embolism) when it is prescribed at 10-mg twice-daily doses to patients with rheumatoid arthritis.

What You Can Do & How We Can Help

The Monsour Law Firm is currently accepting Xeljanz induced injury cases. If you or somebody you know has been diagnosed with blood clots or suffered death after taking Xeljanz, you should contact our lawyers immediately for a free case consultation.

GET A COMPLIMENTARY CASE REVIEW

The Monsour Law Firm will represent you with the diligence and determination you deserve. We will provide a complimentary case review and recommend a course of action to help you receive the correct compensation for your injuries and financial losses. We can help.​

XELJANZ LINKED TO BLOOD CLOTS AND DEATH

February 2019 — The FDA has issued a Safety Announcement to warn that 10-mg twice-daily doses of Xeljanz increases the risk for death and life-threatening blood clots in the lungs of patients with rheumatoid arthritis.


“A safety clinical trial found an increased risk of blood clots in the lungs and death when a 10-mg twice-daily dose of tofacitinib (Xeljanz, Xeljanz XR) was used in patients with rheumatoid arthritis (RA).”


The FDA has not approved this 10-mg twice-daily dose for the treatment of rheumatoid arthritis. This dose is only approved in the dosing regimen for patients with ulcerative colitis.

XELJANZ AND RHEUMATOID ARTHRITIS

Xeljanz® (tofactinib) was approved by the FDA for the treatment of rheumatoid arthritis in 2012. It works by decreasing the activity of the immune system. In patients with rheumatoid arthritis, the immune system attacks its own joints, causing severe pain and swelling.

XELJANZ SAFETY STUDY

As a condition of approval, the FDA required Pfizer to conduct a study to investigate the risk of possible side effects like heart-related events, cancer, and certain infections.The study involved patients who were at least 50 years old with at least one cardiovascular risk-factor.

SAFETY COMMITTEE FINDS HIGHER RISK FOR PULMONARY EMBOLISM AND DEATH

During the analysis of the study, an external safety-monitoring committee found an increased risk of death and blood clots in the lungs (pulmonary embolism) in patients who were taking Xeljanz (10-mg) twice-daily compared to to patients who were taking Xeljanz (5-mg) twice-daily or a TNF inhibitor.

FDA: DOCTORS SHOULD PRESCRIBE RECOMMENDED DOSES OF XELJANZ

The FDA urges doctors to prescribe Xeljanz at the recommended doses. The 10-mg twice-daily dose that is linked to blood clots and death is NOT approved for rheumatoid arthritis patients - however, it is approved for patients with ulcerative colitis.

WHAT SHOULD I DO?

Doctors should also watch patients for signs and symptoms of blood clots or pulmonary embolism. Patients should be instructed to seek medical care immediately if these symptoms occur, the FDA warned.

WARNING SIGNS & SYMPTOMS OF PULMONARY EMBOLISM

  • Sudden trouble breathing
  • Shortness of breath
  • Chest pain (or back pain)
  • Coughing up blood
  • Severe sweating
  • Skin that is clammy or bluish-colored

DO I HAVE A XELJANZ LAWSUIT?

The Monsour Law Firm is currently accepting Xeljanz induced injury cases. If you or somebody you know has been diagnosed with blood clots or suffered death after taking Xeljanz, you should contact our lawyers immediately for a free case consultation.

GET A COMPLIMENTARY CASE REVIEW

The Monsour Law Firm will represent you with the diligence and determination you deserve. We will provide a complimentary case review and recommend a course of action to help you receive the correct compensation for your injuries and financial losses. We can help.​